Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables - Other: 2015-2023

Historic Receivables - Other for Intellia Therapeutics (NTLA) over the last 8 years, with Dec 2023 value amounting to $1.0 million.

  • Intellia Therapeutics' Receivables - Other fell 37.50% to $1.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.0 million, marking a year-over-year decrease of 37.50%. This contributed to the annual value of $1.0 million for FY2023, which is 37.50% down from last year.
  • As of FY2023, Intellia Therapeutics' Receivables - Other stood at $1.0 million, which was down 37.50% from $1.6 million recorded in FY2022.
  • In the past 5 years, Intellia Therapeutics' Receivables - Other registered a high of $3.6 million during FY2019, and its lowest value of $100,000 during FY2021.
  • Moreover, its 3-year median value for Receivables - Other was $1.0 million (2023), whereas its average is $900,000.
  • As far as peak fluctuations go, Intellia Therapeutics' Receivables - Other tumbled by 40.00% in 2019, and later soared by 1,500.00% in 2022.
  • Over the past 4 years, Intellia Therapeutics' Receivables - Other (Yearly) stood at $3.6 million in 2019, then reached $100,000 in 2021, then soared by 1,500.00% to $1.6 million in 2022, then slumped by 37.50% to $1.0 million in 2023.